MICHAEL POLYDEFKIS

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology BALTIMORE, MD NPI 1194768614

General Payments — all program years on this page

$365,735.06

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 180
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $16,386.34 across 16 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $14,358.004
Travel and Lodging $1,527.346
Food and Beverage $501.006

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Acerta Pharma LLC $10,535.285
VERTEX PHARMACEUTICALS INCORPORATED $2,915.207
Alexion Pharmaceuticals, Inc. $2,655.001
Alnylam Pharmaceuticals Inc. $222.262
ARGENX US, INC. $58.601

By program year

Program yearAmountRecords
2018 $4,410.001
2019 $79,416.04103
2020 $27,412.7416
2021 $16,312.509
2022 $208,488.1925
2023 $13,309.2510
2024 $16,386.3416

Records — PY2024 (16)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1093942761 Alexion Pharmaceuticals, Inc. $2,655.00 01/17/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1104209079 AstraZeneca Pharmaceuticals LP $206.50 02/07/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1104343112 AstraZeneca Pharmaceuticals LP $7,518.00 05/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1104589188 AstraZeneca Pharmaceuticals LP $32.00 02/07/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1104669479 AstraZeneca Pharmaceuticals LP $93.78 06/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105253631 AstraZeneca Pharmaceuticals LP $2,685.00 10/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1105904280 VERTEX PHARMACEUTICALS INCORPORATED $582.10 04/10/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1105904953 VERTEX PHARMACEUTICALS INCORPORATED $300.79 04/10/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1105914640 VERTEX PHARMACEUTICALS INCORPORATED $19.15 01/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105918772 VERTEX PHARMACEUTICALS INCORPORATED $107.21 04/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105919466 VERTEX PHARMACEUTICALS INCORPORATED $1,500.00 04/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1105923597 VERTEX PHARMACEUTICALS INCORPORATED $38.00 04/10/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1105924303 VERTEX PHARMACEUTICALS INCORPORATED $367.95 04/10/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1125837583 Alnylam Pharmaceuticals Inc. $123.34 05/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1125837601 Alnylam Pharmaceuticals Inc. $98.92 06/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142120575 ARGENX US, INC. $58.60 06/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.